Multiple endogenous receptors for M2 macrophage-derived factors

Multiple endogenous receptors for M2 macrophage-derived factors refers to the collective group of cell-surface receptors that respond to the secretome of alternatively activated (M2) macrophages. These factors include anti-inflammatory cytokines like IL-10, growth factors such as TGF-beta, VEGF, and EGF, and various chemokines like CCL18 and CCL22. These receptors, which include IL-10 receptors, TGF-beta receptors, and VEGFRs, play a critical role in mediating the pro-regenerative, anti-inflammatory, and pro-angiogenic effects of M2 macrophages in the body. In a therapeutic context, this 'target' is often associated with regenerative medicine products or secretome-based therapies where a mixture of M2 macrophage-derived factors is administered to promote wound healing or tissue repair. Conversely, in oncology, these receptors and their ligands are often viewed as therapeutic challenges, as they contribute to the immunosuppressive and pro-metastatic environment of the tumor microenvironment. Drugs targeting this system may either act as agonists to stimulate healing or as antagonists (such as decoy receptors like aflibercept) to block the pro-tumorigenic effects of specific factors like VEGF.

Other names

M2 macrophage-derived factor receptorsReceptors for M2 macrophage secretomeM2 macrophage-derived factors (M2-MD) receptors

Agonism of multiple endogenous receptors (e.g., IL-10R, TGFBR, VEGFR) by a cocktail of macrophage-secreted factors to promote tissue repair and anti-inflammatory responses.